Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
1. S&P 500 is up over 13% year-to-date, yet healthcare lags behind. 2. Healthcare ETFs trade below parity due to administration policies impacting costs. 3. Concerns rise over higher premiums from tariffs and drug price alignment. 4. Contrarian strategies may benefit healthcare sector amid tech valuations. 5. CURE ETF showcases resilience but has lost over 40% in the past year.